Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable Prognosis

Inclusion Criteria: • Patients \>18 years old undergoing surgical treatment with curative intent for pancreatic and ampullary adenocarcinoma between 1/1/2010 and 31/12/2017 with a regular follow-up and a RFS ≥36 months including: * Patients with locoregional lymph node metastases found at final pathology; * Patients with residual microscopic disease found at final pathology (R1 resections); * Presence of minimal extra-regional disease not detected pre-operatively (nodule of carcinosis, single liver metastasis, single extra-regional lymph node) and removed with the primary tumor within the same intervention. Exclusion Criteria: * Patients undergoing preoperative radiotherapy/chemotherapy for borderline resectable or initially unresectable tumors converted to surgical resection; * Patients with residual macroscopic disease after surgery (R1 resections); * Patients with metastatic disease found at laparotomy and contraindicating surgical resection, including unknown liver metastases, peritoneal carcinomatosis, distant lymph node disease; * Patients with unavailable follow-up or surgical samples for gene analysis.